Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bozong Tang, Jianliang Zhang, Zongguo Yang, Yunfei Lu, Qingnian Xu, Xiaorong Chen, Jiang Lin, Bozong Tang, Jianliang Zhang, Zongguo Yang, Yunfei Lu, Qingnian Xu, Xiaorong Chen, Jiang Lin

Abstract

Background. The complementary and alternative medicines in treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) are controversial. Methods. We searched PubMed, Ovid Embase, Web of Science, Cochrane Library databases, CNKI, Wanfang Database, CBM, VIP, and AMED for randomized controlled trials (RCTs) of moxibustion compared with pharmacological medications in patients with IBS-D. A meta-analysis was performed using both fixed and random-effects models based on heterogeneity across studies. Results. In total, 568 patients in 7 randomized controlled trials were randomly treated with moxibustion and pharmacological medications. The improvement of global IBS-D symptoms and overall scores was significant (P = 0.0001 and P < 0.0001, resp.) in patients treated by moxibustion only compared to pharmacological medications. The specific IBS-D symptoms of abdominal pain, abdominal distension, abnormal stool, and defecation frequency were alleviated in patients treated by moxibustion compared to pharmacological medications, but no significance was found except for abdominal distension and defecation frequency (P = 0.03 and P = 0.02, resp.). There were no serious adverse events related to moxibustion. Conclusions. Moxibustion appears to be effective in treating IBS-D compared with pharmacological medications. However, further large, rigorously designed trials are warranted due to insufficient methodological rigor in the included trials.

Figures

Figure 1
Figure 1
Flow diagram of the study selection process.
Figure 2
Figure 2
Risk of bias assessment.
Figure 3
Figure 3
Improvement of overall IBS-D symptoms and scores.
Figure 4
Figure 4
Improvement of specific IBS-D symptoms.

References

    1. Brandt L. J., Chey W. D., Foxx-Orenstein A. E., et al. An evidence-based position statement on the management of irritable bowel syndrome. American Journal of Gastroenterology. 2009;104(supplement 1):S1–S35.
    1. Rey E., Talley N. J. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Digestive and Liver Disease. 2009;41(11):772–780. doi: 10.1016/j.dld.2009.07.005.
    1. Hungin A. P. S., Chang L., Locke G. R., Dennis E. H., Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Alimentary Pharmacology & Therapeutics. 2005;21(11):1365–1375. doi: 10.1111/j.1365-2036.2005.02463.x.
    1. Drossman D. A., Morris C. B., Schneck S., et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. Journal of Clinical Gastroenterology. 2009;43(6):541–550. doi: 10.1097/mcg.0b013e318189a7f9.
    1. Ringel Y., Williams R. E., Kalilani L., Cook S. F. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clinical Gastroenterology and Hepatology. 2009;7(1):68–72. doi: 10.1016/j.cgh.2008.07.008.
    1. Inadomi J. M., Fennerty M. B., Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Alimentary Pharmacology Therapeutics. 2003;18(7):671–682.
    1. McFarland L. V. State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World Journal of Gastroenterology. 2008;14(17):2625–2629. doi: 10.3748/wjg.14.2625.
    1. Carmona-Sánchez R., Tostado-Fernández F. A. Prevalence of use of alternative and complementary medicine in patients with irritable bowel syndrome, functional dyspepsia and gastroesophageal reflux disease. Revista de gastroenterología de México. 2005;70(4):393–398.
    1. Magge S., Lembo A. Complementary and alternative medicine for the irritable bowel syndrome. Gastroenterology Clinics of North America. 2011;40(1):245–253. doi: 10.1016/j.gtc.2010.12.005.
    1. Yoon S. L., Grundmann O., Koepp L., Farrell L. Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches. Alternative Medicine Review. 2011;16(2):134–151.
    1. Hu D., Kang M., Xiong J., Deng P. Irritable bowel syndrome with diarrhea (IBS-D) treated with moxibustion on heat-sensitive acupoints: a randomized controlled trial. World Journal of Acupuncture—Moxibustion. 2012;22(2):1–5. doi: 10.1016/s1003-5257(12)60019-1.
    1. Ni Y. Y., Lu J. Q. Clinical research on moxibustion treatment of diarrhea type irritable bowel syndrome. World Journal of Acupuncture-Moxibustion. 2001;11(3):19–23.
    1. Park J.-W., Lee B.-H., Lee H. Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis. BMC Complementary and Alternative Medicine. 2013;13, article 247:1–14. doi: 10.1186/1472-6882-13-247.
    1. Hu D., Kang M., Xiong J., et al. Irritable bowel syndrome with diarrhea (IBS-D) treated with moxibustion on heat-sensitive acupoints: a randomized controlled trial. World Journal of Acupuncture-Moxibustion. 2012;22(2):1–5.
    1. Luo S. J., Long J. H., Huang L. The curative effect observation and nursing of moxibustion combined with pinaverium bromide tablets to cure abdominal pain and diarrhea intestine irritable syndrome. Journal of Jinggangshan Medical College. 2008;15(4):39–40.
    1. Zhang Y. B., Yan C. Y., Xie S. Thirty cases of diarrhea-predominant irritable bowel syndrome treated by ginger-partitioned moxibustion. Jiangxi Journal of Traditional Chinese Medicine. 2007;38(296):69–70.
    1. Jin G. D. The efficiency observation of tianjiu therapy on irritable bowel syndrome of diarrhea type. Journal of Zhejiang College of Traditional Chinese Medicine. 2009;33(3):415–416.
    1. Sheng C., Dongqing D., Ma Y., Wang Z., Gao S., Wang X. clinical study on herbal cone-partitioned moxibustion for irritable bowel syndrome due to spleen-qi deficiency. Journal of Acupuncture and Tuina Science. 2011;9(5):265–268.
    1. Chu H., Huang X., Li X., Chen H., Ding Y. Moxibustion for diarrhea-type irritable bowel syndrome: a clinical study. Journal of Anhui TCM College. 2011;30(6):33–36.
    1. Chen S. X., Wang Y. W. Thirty two cases of diarrhea-predominant irritable bowel syndrome treated by heat-sensitive moxibustion. Zhejiang Journal of Traditional Chinese Medicine. 2013;48(3):199–120.
    1. Ma Y.-X., Liu X., Liu C.-Z., et al. Randomized clinical trial: the clinical effects of herb-partitioned moxibustion in patients with diarrhoea-predominant irritable bowel syndrome. Evidence-Based Complementary and Alternative Medicine. 2013;2013:8. doi: 10.1155/2013/605460.605460
    1. Higgins J. P. T., Green S., editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011. (Version 5.1.0). .
    1. Luo J., Leng W. D., editors. Theory & Practice of Systematic Review/Meta-Analysis. Beijing, China: Military Medical Science Press; 2013.
    1. Higgins J. P. T., Thompson S. G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. 2002;21(11):1539–1558. doi: 10.1002/sim.1186.
    1. Cash B. D., Chey W. D. Diagnosis of irritable bowel syndrome. Gastroenterology Clinics of North America. 2005;34(2):205–220. doi: 10.1016/j.gtc.2005.03.001.
    1. Drossman D. A., Dumitrascu D. L. Rome III: new standard for functional gastrointestinal disorders. Journal of Gastrointestinal and Liver Diseases. 2006;15(3):237–241.
    1. Zhou S. Q., Li D. G. The epidemic survey of Fujian teenagers with irritable bowel syndrome. Chinese Journal of Digestive Diseases. 2007;27(3):169–173.
    1. Longstreth G. F., Thompson W. G., Chey W. D., Houghton L. A., Mearin F., Spiller R. C. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491. doi: 10.1053/j.gastro.2005.11.061.
    1. Bundeff A. W., Woodis C. B. Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Annals of Pharmacotherapy. 2014;48(6):777–784. doi: 10.1177/1060028014528151.
    1. Zakko S., Barton G., Weber E., Dunger-Baldauf C., Rühl A. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology and Therapeutics. 2011;33(12):1311–1321. doi: 10.1111/j.1365-2036.2011.04656.x.
    1. Ortiz-Lucas M., Tobías A., Saz P., Sebastián J. J. Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis. Revista Espanola de Enfermedades Digestivas. 2013;105(1):19–36. doi: 10.4321/s1130-01082013000100005.
    1. Rezaie A., Nikfar S., Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Archives of Medical Science. 2010;6(1):49–55. doi: 10.5114/aoms.2010.13507.
    1. Dorn S. D., Kaptchuk T. J., Park J. B., et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterology and Motility. 2007;19(8):630–637. doi: 10.1111/j.1365-2982.2007.00937.x.
    1. Qi L., Liu H.-R., Yi T., et al. Warming moxibustion relieves chronic visceral hyperalgesia in rats: relations to spinal dynorphin and orphanin-FQ system. Evidence-Based Complementary and Alternative Medicine. 2013;2013:10. doi: 10.1155/2013/920675.920675
    1. Zhou E.-H., Wang X.-M., Ding G.-H., et al. Suspended moxibustion relieves chronic visceral hyperalgesia and decreases hypothalamic corticotropin-releasing hormone levels. World Journal of Gastroenterology. 2011;17(5):662–665. doi: 10.3748/wjg.v17.i5.662.
    1. Wu L. Y., Bao C. H., Ge L. B., et al. Mild moxibustion at tianshu (ST 25) decreases expression of prokineticin-1 and prokineticin receptor-1 in colon tissue of rats with chronic visceral hyperalgesia. Neural Regeneration Research. 2011;6(33):2600–2604. doi: 10.3969/j.issn.1673-5374.2011.33.007.
    1. Liu H. R., Hua X. G., Yang Y., Wu H. G. Clinical study on 5-HT expression in colonic mucosa and the treatment of herb-partition moxibustion in diarrhea-predominant IBS. Liaoning Zhongyi Zazhi. 2006;33(8):984–985.
    1. Saito Y. A., Schoenfeld P., Locke G. R., III The epidemiology of irritable bowel syndrome in North America: a systematic review. The American Journal of Gastroenterology. 2002;97(8):1910–1915. doi: 10.1016/s0002-9270(02)04270-3.
    1. Park J.-W., Lee B.-H., Lee H. Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis. BMC Complementary and Alternative Medicine. 2013;13, article 247:14. doi: 10.1186/1472-6882-13-247.
    1. Wu H. G., Zhao C., Shi Z., Chen H. P., Liu Y., Liu S. M. Clinical study on spleen-stomach-reinforcing moxibustion treatment of diarrhea-type irritable bowel syndrome. World Journal of Acupunct-Moxibust. 2002;12(1):10–15.
    1. Wilson A., Longstreth G. F., Knight K., et al. Quality of life in managed care patients with irritable bowel syndrome. Managed Care Interface. 2004;17(2):24–34.
    1. Park J. M., Choi M.-G., Kim Y. S., et al. Quality of life of patients with irritable bowel syndrome in Korea. Quality of Life Research. 2009;18(4):435–446. doi: 10.1007/s11136-009-9461-7.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj